Benjamin Ellingson
Overview
Explore the profile of Benjamin Ellingson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Strowd R, Ellingson B, Raymond C, Yao J, Wen P, Ahluwalia M, et al.
J Neurooncol
. 2023 Oct;
165(1):101-112.
PMID: 37864646
Introduction: Hypoxia inducible factor 2-alpha (HIF2α) mediates cellular responses to hypoxia and is over-expressed in glioblastoma (GBM). PT2385 is an oral HIF2α inhibitor with in vivo activity against GBM. Methods:...
2.
Hazany S, Nguyen K, Lee M, Zhang A, Mokhtar P, Crossley A, et al.
J Clin Neurosci
. 2022 Oct;
105:131-136.
PMID: 36183571
Background: Current methods for quantitative assessment of cerebral small vessel disease (CSVD) ignore critical aspects of the disease, namely lesion type and regionality. We developed and tested a new scoring...
3.
Nguyen H, Nguyen N, Liu L, Dovek L, Lenchner D, Harris R, et al.
Neurooncol Pract
. 2019 Aug;
6(2):103-111.
PMID: 31386050
Background: Since its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first...
4.
Ratai E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, et al.
PLoS One
. 2018 Jun;
13(6):e0198548.
PMID: 29902200
A multi-center imaging trial by the American College of Radiology Imaging Network (ACRIN) "A Multicenter, phase II assessment of tumor hypoxia in glioblastoma using 18F Fluoromisonidazole (FMISO) with PET and...
5.
Tubi M, Lutkenhoff E, Blanco M, McArthur D, Villablanca P, Ellingson B, et al.
Neurobiol Dis
. 2018 Jun;
123:115-121.
PMID: 29859872
Objective: Injury severity after traumatic brain injury (TBI) is a well-established risk factor for the development of post-traumatic epilepsy (PTE). However, whether lesion location influences the susceptibility of seizures and...
6.
Hathout L, Ellingson B, Pope W
Cancer Sci
. 2016 May;
107(8):1110-6.
PMID: 27240229
Standard therapy for glioblastoma (GBM) includes maximal surgical resection and radiation therapy. While it is established that radiation therapy provides the greatest survival benefit of standard treatment modalities, the impact...
7.
Lazovic J, Guo L, Nakashima J, Mirsadraei L, Yong W, Kim H, et al.
Neuro Oncol
. 2014 Jul;
17(1):53-62.
PMID: 25074541
Background: Nitroxoline is an FDA-approved antibiotic with potential antitumor activity. Here we evaluated whether nitroxoline has antiproliferative properties on glioma cell growth in vitro and in vivo using glioma cell...
8.
Connolly M, Bilgin-Freiert A, Ellingson B, Dusick J, Liebeskind D, Saver J, et al.
Clin Neurol Neurosurg
. 2013 Aug;
115(10):2124-9.
PMID: 23958050
Objectives: Remote ischemic preconditioning (RIPC) is a powerful endogenous mechanism whereby a brief period of ischemia is capable of protecting remote tissues from subsequent ischemic insult. While this phenomenon has...